Regeneron Pharmaceuticals/ US75886F1075 /
| 2024-12-20 9:59:50 PM | Chg. -5.87 | Volume | Bid10:25:01 PM | Ask10:25:01 PM | Market Capitalization | Dividend Y. | P/E Ratio |
|---|---|---|---|---|---|---|---|
| 702.03USD | -0.83% | 21,325 Turnover: 5.06 mill. |
-Bid Size: - | -Ask Size: - | 77.13 bill.USD | - | 18.94 |
Assets
|
2019 US GAAP in mill. USD |
2020 US GAAP in mill. USD |
2021 US GAAP in mill. USD |
2022 US GAAP in mill. USD |
2023 US GAAP in mill. USD |
||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Property and Equipment | 2,890.4000 | 3,221.6000 | 3,482.2000 | 3,763 | 4,146.4000 | ||||||
| Intangible Assets | - | - | - | 915.5000 | 1,038.6000 | ||||||
| Long-Term Investments | 3,256.8000 | 3,135.6000 | 6,838 | 6,591.8000 | 5,396.5000 | ||||||
| Fixed Assets | 7,116.1000 | 7,384.2000 | 11,419.9000 | 13,330.4000 | 13,601 | ||||||
| Inventories | 1,415.5000 | 1,916.6000 | 1,951.3000 | 2,401.9000 | 2,580.5000 | ||||||
| Accounts Receivable | 2,100 | 3,111.5000 | 6,036.5000 | 5,328.7000 | 5,667.3000 | ||||||
| Cash and Cash Equivalents | 1,617.8000 | 2,193.7000 | 2,885.6000 | 3,105.9000 | 2,730 | ||||||
| Current Assets | 7,689.1000 | 9,779.1000 | 14,014.9000 | 15,884.1000 | 19,479.2000 | ||||||
| Total Assets | 14,805.2000 | 17,163.3000 | 25,434.8000 | 29,214.5000 | 33,080.2000 | ||||||
Liabilities
|
2019 US GAAP in mill. USD |
2020 US GAAP in mill. USD |
2021 US GAAP in mill. USD |
2022 US GAAP in mill. USD |
2023 US GAAP in mill. USD |
||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Accounts Payable | 418.1000 | 475.5000 | 564 | 589.2000 | 606.6000 | ||||||
| Long-term debt | 713.9000 | 2,695.7000 | 1,980 | 2,701.4000 | 2,702.9000 | ||||||
| Liabilities to Banks | - | - | - | - | - | ||||||
| Provisions | - | - | - | - | - | ||||||
| Liabilities | 3,715.5000 | 6,138 | 6,666 | 6,550.5000 | 7,107.1000 | ||||||
| Share Capital | .1000 | .1000 | .1000 | .1000 | .1000 | ||||||
| Total Equity | 11,089.7000 | 11,025.3000 | 18,768.8000 | 22,664 | 25,973.1000 | ||||||
| Minority Interests | - | - | - | - | - | ||||||
| Total liabilities equity | 14,805.2000 | 17,163.3000 | 25,434.8000 | 29,214.5000 | 33,080.2000 | ||||||
Income Statement
|
2019 US GAAP in mill. USD |
2020 US GAAP in mill. USD |
2021 US GAAP in mill. USD |
2022 US GAAP in mill. USD |
2023 US GAAP in mill. USD |
||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenues | 7,863.4000 | 8,497.1000 | 16,071.7000 | 12,172.9000 | 13,117.2000 | ||||||
| Depreciation (total) | - | - | - | - | - | ||||||
| Operating Result | 2,209.8000 | 3,576.6000 | 8,946.8000 | 4,738.9000 | 4,047.1000 | ||||||
| Interest Income | -30.2000 | -56.9000 | -57.3000 | -59.4000 | -73 | ||||||
| Income Before Taxes | 2,429.1000 | 3,810.4000 | 9,325.8000 | 4,858.8000 | 4,199.3000 | ||||||
| Income Taxes | -313.3000 | 297.2000 | 1,250.5000 | 520.4000 | 245.7000 | ||||||
| Minority Interests Profit | - | - | - | - | - | ||||||
| Net Income | 2,115.8000 | 3,513.2000 | 8,075.3000 | 4,338.4000 | 3,953.6000 | ||||||
Per Share
Cash Flow
|
2019 US GAAP in mill. USD |
2020 US GAAP in mill. USD |
2021 US GAAP in mill. USD |
2022 US GAAP in mill. USD |
2023 US GAAP in mill. USD |
||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash Flow from Operating Activities | 2,430 | 2,618.1000 | 7,081.3000 | 5,014.9000 | 4,594 | ||||||
| Cash Flow from Investing Activities | -2,027.8000 | -70.6000 | -5,384.7000 | -3,784.6000 | -3,185.1000 | ||||||
| Cash Flow from Financing | -252.1000 | -1,970.5000 | -1,005.8000 | -1,009 | -1,790.1000 | ||||||
| Decrease / Increase in Cash | 150.1000 | 577 | 690.8000 | 221.3000 | -381.6000 | ||||||
| Employees | 8,100 | 9,123 | 10,368 | - | - | ||||||
